This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Charles Marwick

JAMA. 2000;284:1503-1505.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Washington—Excitement at the World Alzheimer Congress 2000 centered on the announcement that a phase 1 study of a vaccine that may be used to treat and perhaps prevent the progression of Alzheimer disease (AD) has begun in the United States and United Kingdom.

As became clear from more than 1000 technical reports and reviews presented during the congress, the vaccine approach could not have come this far without many previous studies of the pathogenesis of what still remains a puzzling disorder with no effective treatment. "The really exciting stuff was reported over the past few years, as a result of the identification of the causative genes involved in the inherited form of AD—amyloid precursor protein [APP], presenilin 1, and presenilin 2—were clarified," said Donald Price, MD, professor of pathology, neurology, and neuroscience at Johns Hopkins University School of Medicine, in an interview. "What we are seeing now . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?